Category: Trading Advice

ThermoGenesis Holdings, Inc. (THMO) has experienced an increase of 7.58% in the aftermarket. However, the last trading session closed at $1.98 with an incline of 0.51%. Automated manufacturing of Gene-engineered Autologous Cell (GEAC) Therapies THMO reported on 14th September 2021 that it has received a $250,000 Phase I SBIR funding. The funding is meant to design and test the single-use sterile cell processing disposable. These programs enable US-owned life science firms to participate in government research and development with a high potential for commercialization that aligns with the NIH’s objective of improving health and saving lives. Existing X-Series cartridges have

Lion Group Holdings Ltd. (LGHL) stock prices were up by 23.54% some time after market trading commenced on October 1st, 2021. This brought the price per share up to USD$1.57 early on in the trading day. Total Revenue Report LGHL stock reported total revenues in the amount of USD$3.6 million for the first half of fiscal 2021. These represent a 44% year-over-year decrease from the USD$6.4 million reported for the same time period in the prior year. The yearly difference was largely attributable to a decrease in market marking commission income and trading gains/losses. A decrease in insurance brokerage income

Progenity, Inc. (PROG) has experienced an incline of 32.24% in the premarket today. However, the last trading session closed at $1.52 with an incline of 40.74%. 11th Annual Partnership Opportunities PROG announced on 21st September 2021 that it would attend the 11th annual Partnership Opportunities in Drug Delivery (PODD) Conference. It will take place in Boston on October 28-29, 2021. Chris Wahl will speak on the panel Orally Ingestible Devices for Biologics Delivery. Progenity’s Oral Biotherapeutic Administration System (OBDS) is designed to provide needle-free systemic delivery of large-molecule biologics in a liquid formulation, will be discussed during the session. The

Superior Drilling Products, Inc. (SDPI) has experienced a decline of 16.57% in the premarket. However, the last trading session closed at $1.75 with an increase of 60.55%. Second Quarter 2021 results SDPI reported second-quarter 2021 results on 13th August 2021. Operating income of $116 thousand was achieved as a consequence of higher revenue and decreased operating expenditures. As a consequence of the timing of expenditures linked to year-end close and the reduction in amortization expense, total operating expenses dropped 3% over the preceding first quarter. The quarter’s net loss was nearly breakeven at $67 thousand, compared to a net loss

Lordstown Motors Corp. (RIDE) stock has surged 8.9% in the aftermarket because RIDE Provides Production and Financial updates. However, the last trading session closed at $7.98 with an incline of 8.42%. Production and Financial Update RIDE announced Production and Financial Update on 30th September 2021. Firstly, the capital expenditures remained unchanged from $375 million to $400 million. This owed to changes in the timing of tooling and equipment purchases. Secondly, the SG&A expenses were $105 to $120 million, up from $95 to $105 million. This indicated the increased legal and professional fees. Thirdly, R&D expenses came out to be $320

CynergisTek Inc. (CTEK) stock prices were up by 1.10% shortly after market trading commenced trading on September 30th, 2021. This brought the price per share up to USD$1.84 early on in the trading day. CTEK Stock’s New Contract September 30th, 2021 saw CTEK stock announce having been selected for a new contract by one of the largest U.S based federal credit unions. The contract has been valued at nearly USD$300,000 and will facilitate the provision of Red Team and Security Assessment services. With cybersecurity becoming an increasingly critical priority for financial institutions, competition within the company’s marketspace is intense. Credit

Nxt-ID, Inc. (NXTD), a company providing technology products and services for healthcare applications, has increased 2.58% in the premarket session. Consequently, NXTD stock is changing hands at $0.39 at the time of this writing. The increase has come after the company wrote a letter to shareholders. The company urged them to vote for the reverse stock split. On Wednesday, NXTD stock closed the day at $0.38 following a decline of 3.53%. NXTD letter to shareholders NXTD, on Wednesday, sent a letter to its shareholders. The letter was from the company’s chief executive Chia-Lin Simmons about the company’s upcoming Special Meeting of

Shares of the Dollar Tree, Inc. (DLTR) stock were climbing today after it announced the increase in the share buyback program. DLTR stock price saw a push of 13.53% to reach $97.95 a share at the time of this writing. The stock was red in the previous trade and went down by 0.68% with an $86.28 per share price. Let’s deep dive to explore more of it. Dollar Tree, Inc, founded in 1986, is operating by running discount variety retail stores. The company is operating via two segments, Dollar Tree and Family Dollar. There are 7,805 stores under the Dollar

Molecular Data Inc. (MKD) stock prices were down by 1.22% as of the market closing on September 28th, 2021. This brought the price per share down to USD$0.29 at the end of the trading day. Subsequent premarket fluctuations have seen the stock rise by 2.99%, bringing it up to USD$0.30. Registered Direct Offering September 22nd 2021 saw MKD stock announce the closure of its previously announced registered direct offering. The company put up common units up for purchase, each of which consists of one American Depositary Share. Each ADS represents three of its Class A ordinary shares and one warrant

Iterum Therapeutics plc (ITRM) has experienced an increase of 24.37% in the premarket today after ITRM Provides Update from FDA Type A Meeting Regarding Oral Sulopenem. However, the last trading session closed at $0.5548 with an increase of 0.49%. Update from FDA Type A Meeting Regarding Oral Sulopenem On 28th September 2021, ITRM declared that during the third quarter of 2021, the Company held a Type A meeting with the US Food and Drug Administration. It was to explain the steps required for a potential renewal of the New Drug Application. The FDA sent the company a Complete Response Letter